CHENGDU, China, May 23, 2025 /PRNewswire/ -- The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, the "Company") will present results from six clinical studies, including data on its TROP2 ADC sac-TMT, anti-PD-L1 mAb tagitanlimab, and RET inhibitor KL590586 (A400/EP0031) during the meeting. The study abstracts were published on the ASCO website o

First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically meaningful results from the phase-III PROTECT trial 4 ST. GALLEN, Switzerland, May 23, 2025 /PRNewswire/ -- CSL Vifor is pleased to announce that the National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending that sparsentan can be used in the NHS in England

PHILADELPHIA, PA, USA I May 22, 2025 I GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab)as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilicphenotype. FDA’s approval was based on data from the positive MATINEE and METREX phase III trials. Across these trials, mepolizumab showed a clinically meaningful and statistically significant reduction in the annualized rate of moder

–  63% response rate observed among 43 evaluable patients –  79% overall survival rate at 12-months; 9 months median progression-free survival UTRECHT, The Netherlands and CAMBRIDGE, MA, USA I May 22, 2025 I Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ® , Triclonics ® and ADClonics ® ), today announced interim clinical data as of a February 27, 2025 data cutoff

Denver (May 22, 2025) — The Colorado Department of Public Health and Environment, the Denver Department of Public Health and Environment, and Denver International Airport (DEN) are notifying the public of a possible measles exposure at Denver International Airport and a nearby hotel. An out-of-state traveler with a confirmed case of measles traveled through Denver International Airport and stayed at the Quality Inn and Suites Denver International Airport while infectious. The individual arrived

The UK's National Institute for Health and Care Excellence (NICE) on Friday issued final draft guidance recommending CSL Vifor’s Filspari (sparsentan) to treat adults in England with primary IgA nephropathy.The favourable decision on the dual endothelin angiotensin receptor antagonist offers a new once-daily oral treatment option to more than 4200 eligible individuals, particularly those with a urine protein excretion of 1.0 g/day or more, or a urine protein-to-creatinine ratio of 0.75 g/g or mo

ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), achieved an overall response rate (ORR) of 36.4% and disease control rate (DCR) of 100% in checkpoint inhibitor (CPI)-resistant melanoma patients in the ongoing STAMINA-01 trial, with one patient maintaining a partial response (PR) and remained on treatment for over 2 years without any safety concerns. In CPI-resistant non-small cell lung cancer (NSCLC), the combination of ATG-

The FDA’s vaccine advisory panel unanimously recommended maintaining JN.1 lineage variants for the forthcoming respiratory virus season's COVID-19 vaccines.The agency’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), which convened on Thursday, delivered its recommendation following a comprehensive assessment of current variant circulation patterns and nonclinical vaccine performance data. All nine participating members voted in favour of targeting newer strains of JN.1, al

Phase 1/2 first-in-human clinical study planned this year SHANGHAI and SAN DIEGO, May 22, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for AVZO-1418/DB-1418, a potential best-in-class, novel EGFR/HER3 bispecific antibo

VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has closed the acquisition to acquire 100% of the issued and outstanding shares of NoBrainer Imaging Centers, Inc. (“NIC”) (the “Transaction”) previously announced on May 13, 2025. The Transaction moves Algernon into the Alzheimer’s Disea